Literature DB >> 33489914

Toward Therapeutic Targeting of Bone Marrow Leukemic Niche Protective Signals in B-Cell Acute Lymphoblastic Leukemia.

Marjorie C Delahaye1, Kaoutar-Insaf Salem1, Jeoffrey Pelletier1, Michel Aurrand-Lions1, Stéphane J C Mancini1.   

Abstract

B-cell acute lymphoblastic leukemia (B-ALL) represents the malignant counterpart of bone marrow (BM) differentiating B cells and occurs most frequently in children. While new combinations of chemotherapeutic agents have dramatically improved the prognosis for young patients, disease outcome remains poor after relapse or in adult patients. This is likely due to heterogeneity of B-ALL response to treatment which relies not only on intrinsic properties of leukemic cells, but also on extrinsic protective cues transmitted by the tumor cell microenvironment. Alternatively, leukemic cells have the capacity to shape their microenvironment towards their needs. Most knowledge on the role of protective niches has emerged from the identification of mesenchymal and endothelial cells controlling hematopoietic stem cell self-renewal or B cell differentiation. In this review, we discuss the current knowledge about B-ALL protective niches and the development of therapies targeting the crosstalk between leukemic cells and their microenvironment.
Copyright © 2021 Delahaye, Salem, Pelletier, Aurrand-Lions and Mancini.

Entities:  

Keywords:  B cell development; B-cell acute lymphoblastic leukemia; bone marrow; leukemic niches; targeted treatments

Year:  2021        PMID: 33489914      PMCID: PMC7820772          DOI: 10.3389/fonc.2020.606540

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  108 in total

1.  The earliest stages of B cell development require a chemokine stromal cell-derived factor/pre-B cell growth-stimulating factor.

Authors:  T Egawa; K Kawabata; H Kawamoto; K Amada; R Okamoto; N Fujii; T Kishimoto; Y Katsura; T Nagasawa
Journal:  Immunity       Date:  2001-08       Impact factor: 31.745

2.  The chemokine receptor CXCR4 enhances integrin-mediated in vitro adhesion and facilitates engraftment of leukemic precursor-B cells in the bone marrow.

Authors:  W Shen; L J Bendall; D J Gottlieb; K F Bradstock
Journal:  Exp Hematol       Date:  2001-12       Impact factor: 3.084

3.  Is high expression of the chemokine receptor CXCR-4 of predictive value for early relapse in childhood acute lymphoblastic leukaemia?

Authors:  Pascale Schneider; Marc Vasse; Aws Al Bayati; Bernard Lenormand; Jean-Pierre Vannier
Journal:  Br J Haematol       Date:  2002-11       Impact factor: 6.998

4.  Effects of the chemokine stromal cell-derived factor-1 on the migration and localization of precursor-B acute lymphoblastic leukemia cells within bone marrow stromal layers.

Authors:  K F Bradstock; V Makrynikola; A Bianchi; W Shen; J Hewson; D J Gottlieb
Journal:  Leukemia       Date:  2000-05       Impact factor: 11.528

5.  Leukaemic transformation of engrafted human marrow cells in vivo.

Authors:  P J Fialkow; E D Thomas; J I Bryant; P E Neiman
Journal:  Lancet       Date:  1971-02-06       Impact factor: 79.321

6.  Sensitizing protective tumor microenvironments to antibody-mediated therapy.

Authors:  Christian P Pallasch; Ilya Leskov; Christian J Braun; Daniela Vorholt; Adam Drake; Yadira M Soto-Feliciano; Eric H Bent; Janine Schwamb; Bettina Iliopoulou; Nadine Kutsch; Nico van Rooijen; Lukas P Frenzel; Clemens M Wendtner; Lukas Heukamp; Karl Anton Kreuzer; Michael Hallek; Jianzhu Chen; Michael T Hemann
Journal:  Cell       Date:  2014-01-30       Impact factor: 41.582

7.  Analysis of the mechanism of adhesion of precursor-B acute lymphoblastic leukemia cells to bone marrow fibroblasts.

Authors:  K Bradstock; V Makrynikola; A Bianchi; K Byth
Journal:  Blood       Date:  1993-12-01       Impact factor: 22.113

8.  Sustained activation of cell adhesion is a differentially regulated process in B lymphopoiesis.

Authors:  Aleksandra M Glodek; Marek Honczarenko; Yi Le; James J Campbell; Leslie E Silberstein
Journal:  J Exp Med       Date:  2003-02-17       Impact factor: 14.307

9.  The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity.

Authors:  Yuchun Nie; Janelle Waite; Faraha Brewer; Mary-Jean Sunshine; Dan R Littman; Yong-Rui Zou
Journal:  J Exp Med       Date:  2004-11-01       Impact factor: 14.307

10.  Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab.

Authors:  Thomas Köhnke; Christina Krupka; Johanna Tischer; Thomas Knösel; Marion Subklewe
Journal:  J Hematol Oncol       Date:  2015-10-08       Impact factor: 17.388

View more
  4 in total

Review 1.  Deciphering Tumor Niches: Lessons From Solid and Hematological Malignancies.

Authors:  Stéphane J C Mancini; Karl Balabanian; Isabelle Corre; Julie Gavard; Gwendal Lazennec; Marie-Caroline Le Bousse-Kerdilès; Fawzia Louache; Véronique Maguer-Satta; Nathalie M Mazure; Fatima Mechta-Grigoriou; Jean-François Peyron; Valérie Trichet; Olivier Herault
Journal:  Front Immunol       Date:  2021-11-10       Impact factor: 7.561

2.  Overcoming Microenvironment-Mediated Chemoprotection through Stromal Galectin-3 Inhibition in Acute Lymphoblastic Leukemia.

Authors:  Somayeh S Tarighat; Fei Fei; Eun Ji Joo; Hisham Abdel-Azim; Lu Yang; Huimin Geng; Khuchtumur Bum-Erdene; I Darren Grice; Mark von Itzstein; Helen Blanchard; Nora Heisterkamp
Journal:  Int J Mol Sci       Date:  2021-11-10       Impact factor: 5.923

3.  Patient-Derived Bone Marrow Spheroids Reveal Leukemia-Initiating Cells Supported by Mesenchymal Hypoxic Niches in Pediatric B-ALL.

Authors:  Juan Carlos Balandrán; José Dávila-Velderrain; Antonio Sandoval-Cabrera; Gabriela Zamora-Herrera; Vanessa Terán-Cerqueda; Lilia Adela García-Stivalet; José Alejandro Limón-Flores; Erick Armenta-Castro; Aurora Rodríguez-Martínez; Bertha Alicia Leon-Chavez; Verónica Vallejo-Ruiz; Duane C Hassane; Sonia Mayra Pérez-Tapia; Vianney Ortiz-Navarrete; Monica L Guzman; Rosana Pelayo
Journal:  Front Immunol       Date:  2021-10-19       Impact factor: 7.561

4.  hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia.

Authors:  Deepali Pal; Helen Blair; Jessica Parker; Sean Hockney; Melanie Beckett; Mankaran Singh; Ricky Tirtakusuma; Ryan Nelson; Hesta McNeill; Sharon H Angel; Aaron Wilson; Salem Nizami; Sirintra Nakjang; Peixun Zhou; Claire Schwab; Paul Sinclair; Lisa J Russell; Jonathan Coxhead; Christina Halsey; James M Allan; Christine J Harrison; Anthony V Moorman; Olaf Heidenreich; Josef Vormoor
Journal:  Cell Rep Med       Date:  2022-08-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.